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Prevention of congenital heart block in children of SSA-positive
mothers
A. Brucato
The incidence of congenital heart block (CHB) in the offspring of anti-Ro-positive women is 1–2%, and the risk of recurrence is 10 times
higher in the following pregnancies. Non-fluorinated steroids (prednisone, prednisolone and methylprednisolone) are recommended only for
maternal indications, not for prevention of CHB in anti-Ro/SSA-positive women. Fluorinated steroids (dexamethasone or bethametasone) are
not metabolized by the placenta and are available to the fetus in an active form. Routine prophylactic therapy with fluorinated steroids is not
recommended even in women who previously had children with CHB or skin rash since this therapy has its own side-effects. Intravenous
immunoglobulin had been used to prevent the development of CHB in 8 high risk mothers (anti-Ro/SSA positive and previous pregnancy with
CHB), and in one case CHB recurred (12.5%). At present, the only sure recommendation that can be made in these women is that in the
presence of reliable positivity for anti-Ro/SSA antibodies serial echocardiograms and obstetric sonograms should be performed at least every
2 weeks starting from the 16th week of gestational age: the goal is to detect early fetal abnormalities, such as premature atrial contractions or
moderate pericardial effusion, that might precede complete atrioventricular block and that might be a target of preventive therapy. Fluorinated
steroids should not be used in the absence of symptoms; in the presence of alarming symptoms, betamethasone seems safer than
dexamethasone.
KEY WORDS: Heart block/congenital, Neonatal lupus, Systemic lupus erythematosus, Sjogren’s syndrome, Undifferentiated connective tissue disease,
Dexamethasone, Betamethasone, Intravenous immunoglobulin, anti-Ro/SSA antibodies, Pregnancy.
Introduction
The incidence of congenital heart block (CHB) in the offspring of
anti-Ro-positive women is 1–2%, and the risk of recurrence of
complete atrioventricular (AV) block is almost 10 times higher in
the following pregnancies. Substantial morbidity (65% require
lifelong pacing) and mortality (20%) are associated with CHB
[1]. Most of the mothers are asymptomatic at delivery and are
identified only by the birth of an affected child.
Pathogenesis
Neonatal lupus is associated with the presence of autoantibodies
directed against the ENAs SSA/Ro and SSB/La [1]. These
antibodies cross the placenta beginning at 16 weeks of gestation
and reach the fetal tissues, where: (i) they might induce a
myocarditis; (ii) they may be arrhythmogenic; and (iii) they can
interfere with apoptosis. The immune-mediated damage of the
cardiac conduction system ultimately ends with its substitution
with fibrotic tissue.
Anti-Ro/SSA 52 kDa antibodies and antibodies directed
against the p200 peptide of the SSA antigen have been linked
more stringently to the development of CHB, but the data are not
conclusive [1].
Risk of occurrence and pre-conceptional counselling
of anti-Ro/SSA-positive mothers
A woman is at risk of delivering a baby affected by complete CHB
if she is definitely anti-Ro/SSA positive. If the positivity is
uncertain or the titre is very low, we advise confirmation of
positivity with standard methods or in reference laboratories. The
risk is 1–2% of anti-Ro/SSA-positive pregnancies. There are
some suggestions that anti-52-kDa Ro/SSA and anti-La/
SSB antibodies are more strongly associated with CHB than
anti-60-kDa Ro/SSA alone (at least as tested by immunoblot),
but the data are incomplete. Furthermore, the problem of
reliability, sensitivity and specificity of the different tests
(commercial kits, home made, etc.) is even greater at this level
of differentiation of the fine specificities.
Since anti-Ro/SSA antibodies are relatively frequent in women,
at least in a rheumatology practice but CHB is very rare, we are
faced with the following situation: frequent counselling about a
rare disease. In a prospective study, we found that the incidence of
CHB in newborns of 100 women already known to be anti-Ro/
SSA-positive and with known CTD was 2% (95% CI 0.2%, 7%)
[2]. We studied only mothers who had been found to be anti-Ro/
SSA positive by counter-immunoelectrophoresis, a method with
high specificity and rather low sensitivity, to exclude women with
low or dubious titres of anti-Ro/SSA. Our results therefore cannot
be extrapolated, for instance, to those with a low positive reaction
for anti-Ro/SSA antibodies by ELISA, for which the risk, if any,
should even be lower. The CHBs were detected at 22 and 20
weeks. One of the two CHB mothers had primary SS, while the
other had UCTD. No case of CHB occurred among 53 SLE
mothers. This finding has now been confirmed by other groups:
Gladman [3] reported no cases of CHB in 100 live births in 96
women with anti-SSA/Ro and/or anti-SSB/La antibodies and no
history of a previous child with neonatal lupus; Cimaz (2003)
observed two cases of CHB out of 128 infants (1.6%) [4],
Costedoat-Chalumeau one case out of 99 infants (1%) [5], and
Gerosa (2007) reported a similar risk [6].
Risk of recurrence
Few prospective studies exist on this issue; the percentage seems
to comprise between 10% and 20%, and therefore substantially
higher than in the first pregnancy [1, 7]. In a nation-wide study
from Finland, the risk of recurrence of CHB was 17% (8 of 47),
and data from the Research Registry for Neonatal Lupus
including 105 affected mothers showed that 19% of pregnancies
immediately subsequent to the birth of a child with CHB resulted
in a second child with CHB [1]. It is also important to underline
that women who have had a prior pregnancy of a child with the
bona fide skin rash of neonatal lupus also have about a 19% risk
of having a subsequent pregnancy with CHB [1].
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Prevention of CHB
Non-fluorinated steroids
Non-fluorinated steroids are recommended only for maternal
indications, and prednisone, prednisolone and methylprednisolone
should be preferred [8]. They are not indicated for prophylaxis of
CHB in anti-Ro/SSA-positive women, even if they had in the past
infants affected by neonatal lupus (CHB or skin rash). These
steroids (at least in low and moderate doses) do not prevent the
development of CHB [1]. This might be anticipated since
prednisone given to the mother does not cross the placenta and
is not active in the fetus and levels of anti-Ro and anti-La
antibodies remain relatively constant during steroid therapy.
Shinohara [9] has reported that pre-natal maintenance therapy
with prednisolone started before 16 weeks’ gestation might reduce
the risk of developing CHB, but this article is heavily biased by the
retrospective setting. In fact, it is now recognized that the majority
of women bearing children with CHB do not have recognized SLE
and are often asymptomatic at the time of delivery, so they are not
pre-treated with steroids: these women would not have been
identified had the fetal abnormality not occurred (retrospective
diagnosis). Furthermore, that study included too few cases to see a
real benefit from steroids, and there are cases of CHB in infants
born to mothers who did take steroids.
Fluorinated steroids
Fluorinated steroids are not metabolized by the placenta and
are available to the fetus in an active form [8]. Routine pro-
phylactic therapy with fluorinated steroids is not recommended
[1, 7]; in fact, the risk is too low to justify treatment with
dexamethasone or betamethasone for all pregnant women who are
anti-Ro/SSA positive, since this therapy has its own side-effects.
Even in women who previously had children with CHB or
neonatal lupus skin rash side-effects profile had been shown to be
unacceptable [10].
Maternal risks of these steroids are similar to any glucocorti-
coid, but for these indications they are usually used at high
dosages (at least 4mg dexamethasone daily) and include infection,
osteoporosis, osteonecrosis and diabetes. Fetal risks include
intrauterine growth restriction and oligohydramnios [8].
Intravenous immunoglobulin
At present the most pressing issue in CHB is the management of a
pregnancy subsequent to the birth of an affected child (recurrence
rate is 16%).
Kaaja and Julkunen [7] used intravenous immunoglobulin
(IVIG) and corticosteroid to prevent the development of CHB in
eight high-risk mothers (anti-Ro/SSA-positive and previous
pregnancy with CHB) [11]. During the pregnancy following the
one that resulted in the birth of an infant with CHB, women were
treated with IVIG 1 g/kg at 14 and 18 weeks of gestation.
Prednisone was started at 14 week of gestation at a dosage of
40mg daily, which was tapered to 20mg daily at 16 weeks and
10mg daily at 24 weeks; prednisone was continued at this latter
dosage for the remainder of the pregnancy. One woman under-
went the IVIG infusions but refused to take prednisone. Seven of
the eight women gave birth to a healthy child without CHB. The
woman who delivered a child with CHB was the one who did not
receive corticosteroids. A reduction in anti-Ro/SSA titres was
observed in six of the eight women. Notably, the overall risk of
recurrence was similar to the expected one: 1/8¼ 12.5% [11]. The
potential mechanisms by which IVIG could prevent the tissue
damage are increased elimination of maternal anti-Ro and anti-La
(idiotype–anti-idiotype regulation), decrease in transplacental
transport of antibodies and modulation of inhibitory signalling
on macrophages with consequent reduction of inflammatory
response and fibrosis. New evidence showing the potential
usefulness of IVIG to prevent CHB was reported by Tran et al.
[12]. In a murine model, maternal administration of IVIG
inhibited the transfer of anti-Ro/La across the placenta and
their susbequent deposition in the fetal heart, most likely by non-
specific blockade of placental Fc receptors.
Based on these data, the English group has proposed at the
Fourth International Conference on Sex Hormones, Pregnancy
and the Rheumatic Diseases, organized by Italian Society of
Rheumatology in Stresa, 2004, a protocol for the prevention
of CHB development in high-risk pregnant women. This is a
prospective, pilot trial of treatment with IVIG to pregnant women
with anti-Ro/SSA antibodies and previous pregnancy with CHB.
The proposed medication regime is infusion of IVIG 0.4 g/kg
given at 12, 15, 18, 21 and 24 weeks of pregnancy in women who
agree to take part. IgA deficiency is an exclusion criterion.
Primary outcome is the development of third-degree CHB.
Enrolment is ongoing.
The incidence of adverse effects with IVIG use ranges between
1% and 15% [13]. The most common side-effect related with the
infusion is the association of headache, fever and flushing,
typically mild and transient. An anaphylactoid reaction is possible
in IgA-deficient patients, but could be avoided by starting IVIG
infusion at low rate to achieve desensitization. Pain in the IV site,
flushing and hypotension may result from the presence of
vasoactive substances. Other less frequent adverse events include
renal dysfunction and acute renal failure related to sucrose
nephropathy. Underlying renal failure and diabetes predisposes to
this complication. In order to minimize the renal effects, all
patients should be well hydrated. Reports of thromboembolic
events have been associated with IVIG use, including venous and
arterial thrombosis.
Possible treatment of early fetal abnormalities
The following suggestions are experimental or based on the
experience of some experts in the field, and not tested in a
controlled trial. First of all, although there is not yet documenta-
tion regarding the reversal of third-degree heart block (presumably
fibrosis of conducting system), the potential for diminishing an
inflammatory fetal response attacking the cells of the conduction
system is plausible. Second, incomplete AV block has been shown
to be potentially reversible [14, 15]; moreover progression of
second-degree AV block to third-degree AV block has been
described, even after birth [1] Third, at first appearance of a fetal
bradycardia it can be extremely difficult and time-consuming to
differentiate between second-degree (incomplete) and third-degree
(complete) AV block [15]. Fourth, until recently the in utero
detection of first-degree AV block was not technically feasible, but
now the electrocardiogram equivalent of the PR interval can be
measured by echocardiography [16]. Using the gated-pulsed
Doppler technique, time intervals from the onset of the mitral
A wave (atrial systole) to the onset of the aortic pulsed Doppler
tracing (ventricular systole) within the same left ventricular cardiac
cycle may be measured [16]. This time interval represents the
mechanical PR interval. Other methods have also been developed
[17], and signs of first-degree heart block may occur in up to one-
third of the fetuses of pregnant women with anti-Ro/SSA 52-kDa
antibodies [17] (though the definition of what time interval equates
with first-degree heart block is not clear). Finally, a very
informative case report has been described by Rosenthal [14],
who described a woman with a previous pregnancy, complicated
by CHB [18]; in the next pregnancy, intensive fetal monitoring
revealed at 21 weeks’ gestation a decrease in left ventricular
function, occasional premature atrial contractions, a moderate
pericardial effusion and a biphasic flow in the inferior vena cava.
All these abnormalities reverted after dexamethasone 4mg once
daily was given, and a male newborn was delivered at 36 weeks’
gestation, with a first-degree AV block present in the ECG. This
case report shows that early and treatable abnormalities may be
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detected and potentially avert deterioration to complete and
permanent block. Unfortunately, it has been reported that one
fetus may progress from abnormal AV time interval to complete
block in 6 days [17], and we observed a case that in 1 week
progressed from a normal echo to a complete heart block with
myocarditis (personal unpublished data). Anyway the goal might
be to detect early fetal abnormalities, that might precede complete
AV block and that might be a target of pre-emptive therapy [1, 7].
In the presence of abnormalities such as these (e.g. premature
atrial contractions or moderate pericardial effusion) [18] we give
betamethasone to the mother, 4–6mg daily. This therapy is
continued for some weeks, according to the evolution of the
clinical features. We acknowledge that this approach is not based
on evidence. We prefer betamethasone to dexamethasone, since the
possible negative effects seem more linked to dexamethasone than
betamethasone [8], and it has been suggested that betamethasone
should be preferred when available [8]. Moreover, separate meta-
analysis of the data in the Cochrane review show that only
betamethasone and not dexamethasone significantly reduces
neonatal mortality [8]. Even a recent trial concluded that ‘pending
a randomized, clinical trial, it may be in the best interests of infants
to receive betamethasone, rather than dexamethasone, when
possible’ [19].
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Rheumatology key messages
 Corticosteroids are not recommended to prevent CHB.
 IVIG had been used in high risk mothers but recurrences were
observed (12.5%).
 Serial echocardiograms are advised to detect early fetal
abnormalities.
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